Can an AI chatbot alleviate postpartum depression in developing regions?

Researchers are looking into whether live and automated text messaging augmented by AI can help treat or ward off postpartum depression for women in Kenya.

Eric Green, PhD, of Duke, Edith Kwobah, MBChB, MMed, of Moi Teaching and Referral Hospital in Kenya, and colleagues published their research protocol online April 29 in the Journal of Medical Internet Research.

In introducing their work, the team points out that depression during pregnancy and in the postpartum period has been associated with a number of poor outcomes for women and their children.

“Although effective interventions exist for common mental disorders that occur during pregnancy and the postpartum period, most cases in low- and middle-income countries go untreated because of a lack of trained professionals,” they write.

The pilot study focuses on adapting the World Health Organization’s “Thinking Healthy” program, which guides mental healthcare for perinatal depression.

The team will build this out by adding an existing smartphone AI chatbot called Tess (Zuri in Kenya) to facilitate targeted talk therapy with both live professionals and automated text messages.

The team adapted the content of the intervention last year after testing it with 10 women at a private maternity hospital. These users offered feedback, and the researchers incorporated their input to fine-tune the innovation.

Recruitment for the Kenya phase of their project began in January. Results are expected toward the end of this year.

Green et al. acknowledge as a limitation their reliance on women who live in and around cities, as much of the Kenyan population lives in rural or remote areas.

“The results of this study may not generalize to the broader population of Kenyan women, but that is not an objective of this phase of work,” they write. “Our primary objective is to gather preliminary data to know how to build and test a more robust service. We are working toward a larger study with a more diverse population.”

To read the complete research protocol, click here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup